Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Friday, November 22, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences will host a virtual investor event on November 15, 2024, to discuss the preclinical safety data of its PBGENE-HBV program and plans for a Phase 1 clinical trial. The event aims to highlight the company's innovative ARCUS platform for gene editing therapies targeting Hepatitis B. This initiative reflects the company's commitment to advancing its gene editing capabilities.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · 4 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing its PBGENE-HBV program.
  • The company is utilizing its novel ARCUS platform for gene editing.
  • The upcoming event will provide insights into preclinical safety data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Oct. 28, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B

Frequently Asked Questions

What is the purpose of the virtual investor event?

The event will highlight PBGENE-HBV preclinical safety data and Phase 1 trial plans.

When is the investor event scheduled?

The virtual investor event is scheduled for November 15, 2024.

What platform is Precision BioSciences using?

The company is utilizing its proprietary ARCUS platform for gene editing.

What disease is PBGENE-HBV targeting?

PBGENE-HBV is focused on developing therapies for Hepatitis B.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-HBV gene editing ARCUS platform Hepatitis B
Last updated: Nov 22, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →